RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains a Sector Perform rating on Gilead Sciences and raises the price target from $74 to $75.
October 04, 2024 | 2:53 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital has maintained its Sector Perform rating on Gilead Sciences and slightly increased the price target from $74 to $75, indicating a stable outlook with minor positive adjustments.
The maintenance of a Sector Perform rating suggests that Gilead Sciences is expected to perform in line with the market. The slight increase in the price target from $74 to $75 indicates a minor positive adjustment in expectations, but not enough to suggest a significant change in stock price direction.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100